Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GlaxoSmithKline

This article was originally published in The Tan Sheet

Executive Summary

Firm is proposing to close three former Block Drug consumer health care product manufacturing sites in Puerto Rico, UK, Ireland over next two years. Operations at these sites are duplicated elsewhere in GSK's network, company says, and can be incorporated into GSK facilities in UK, U.S. Three sites manufacture dental products such as Sensodyne, Poli-Grip, Polident and other smaller brands. GSK completed its purchase of Block in January (1"The Tan Sheet" Jan. 22, In Brief). Block's products eventually will bear GSK name

You may also be interested in...



GlaxoSmithKline

U.S. Consumer Healthcare business considering expansion of Kennedy Twp., Penn. facilities near Pittsburgh or relocation. Firm says SmithKline Beecham/Glaxo Wellcome merger, subsequent Block Drug acquisition are driving need for more office space. GSK previously said it would close three former Block manufacturing sites in Puerto Rico, UK, Ireland over next two years and incorporate operations into GSK facilities (1"The Tan Sheet" June 25, In Brief)

GlaxoSmithKline

U.S. Consumer Healthcare business considering expansion of Kennedy Twp., Penn. facilities near Pittsburgh or relocation. Firm says SmithKline Beecham/Glaxo Wellcome merger, subsequent Block Drug acquisition are driving need for more office space. GSK previously said it would close three former Block manufacturing sites in Puerto Rico, UK, Ireland over next two years and incorporate operations into GSK facilities (1"The Tan Sheet" June 25, In Brief)

GlaxoSmithKline

U.S. Consumer Healthcare business considering expansion of Kennedy Twp., Penn. facilities near Pittsburgh or relocation. Firm says SmithKline Beecham/Glaxo Wellcome merger, subsequent Block Drug acquisition are driving need for more office space. GSK previously said it would close three former Block manufacturing sites in Puerto Rico, UK, Ireland over next two years and incorporate operations into GSK facilities (1"The Tan Sheet" June 25, In Brief)

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS092713

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel